WO1995029694A1 - Accelerateur d'hydrolyse du collegene - Google Patents
Accelerateur d'hydrolyse du collegene Download PDFInfo
- Publication number
- WO1995029694A1 WO1995029694A1 PCT/JP1995/000822 JP9500822W WO9529694A1 WO 1995029694 A1 WO1995029694 A1 WO 1995029694A1 JP 9500822 W JP9500822 W JP 9500822W WO 9529694 A1 WO9529694 A1 WO 9529694A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibrosis
- hgf
- hgfs
- liver
- collagen
- Prior art date
Links
- 102000008186 Collagen Human genes 0.000 title abstract description 12
- 108010035532 Collagen Proteins 0.000 title abstract description 12
- 229920001436 collagen Polymers 0.000 title abstract description 12
- 230000007062 hydrolysis Effects 0.000 title abstract 3
- 238000006460 hydrolysis reaction Methods 0.000 title abstract 3
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 36
- 230000004761 fibrosis Effects 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 27
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 23
- 230000011382 collagen catabolic process Effects 0.000 claims description 18
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 230000001737 promoting effect Effects 0.000 claims description 9
- 230000003176 fibrotic effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 208000011379 keloid formation Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010065584 Urethral stenosis Diseases 0.000 claims description 2
- 238000002574 cystoscopy Methods 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 201000001988 urethral stricture Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000004362 Penile Induration Diseases 0.000 claims 1
- 208000020758 Peyronie disease Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 102000029816 Collagenase Human genes 0.000 abstract description 9
- 108060005980 Collagenase Proteins 0.000 abstract description 9
- 229960002424 collagenase Drugs 0.000 abstract description 9
- 210000002808 connective tissue Anatomy 0.000 abstract description 6
- 210000003494 hepatocyte Anatomy 0.000 abstract description 5
- 239000011159 matrix material Substances 0.000 abstract description 4
- 210000002950 fibroblast Anatomy 0.000 abstract description 3
- 239000003102 growth factor Substances 0.000 abstract 1
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 48
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 40
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 40
- 241000700159 Rattus Species 0.000 description 37
- 238000012360 testing method Methods 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 13
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
- 229960002591 hydroxyproline Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 102000057308 human HGF Human genes 0.000 description 2
- -1 inhalants Substances 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000002865 osteopetrosis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- KVRGDVMQISBTKV-UHFFFAOYSA-N acetic acid;oxalic acid Chemical compound CC(O)=O.OC(=O)C(O)=O KVRGDVMQISBTKV-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000019860 lauric fat Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a collagen degradation promoter and a fibrosis disorder therapeutic agent. More specifically, the present invention relates to a collagen degradation promoter and a therapeutic agent for fibrosis disorders containing HGF (Hepatocyte Growth Facto.r) as an active ingredient.
- HGF Hepatocyte Growth Facto.r
- Fibrosis is a disease characterized by excessive accumulation of connective tissue components. Collagen is the central and most remarkable of fibrosis ⁇ Collagen accumulation occurs in various internal organs, such as lung. In the lung and fibrosis in the liver. It also occurs in the skin, for example, in conditions such as skin keloid formation.
- a variety of medications have been used to treat fibrotic diseases and disorders, but generally they focus on symptomatic treatment of the disorder, with the underlying pathology being the production and production of collagen and other connective tissue components. It was not aimed at overcoming the imbalance among metabolic factors that regulate degradation. Therefore, none of these treatments was particularly effective in improving tissue. That is, for example, if topical corticosteroids have been used with some success in treating the early inflammatory stages of skin keloid production, but the actual production of keloids has resulted from excessive collagen production. At such later stages of fibrosis, such steroids have little or no effect.
- the prior art treats human fibrosis disorders in a safe and effective manner, preventing further generation of fibrotic tissue and reducing the number of fibrosis lesions already generated. And no method to remove or completely remove Was.
- An object of the present invention is to provide a collagen degradation promoter capable of inducing the degradation of collagen matrix in connective tissue excessively accumulated in a tissue and a therapeutic agent useful for treating fibrosis disorders.
- the present inventors have conducted intensive studies in order to solve the above problems,
- the present inventors have found that HGFs have an action of promoting the degradation of collagen, and based on the action, are effective in treating fibrosis disorders, and completed the present invention. That is, the present invention is a collagen degradation promoter comprising at least one HGF as an active ingredient.
- Another invention of the present invention is a therapeutic agent for fibrosis disorders, comprising at least one HGF as an active ingredient.
- Still another aspect of the present invention relates to a method for promoting collagen degradation, comprising administering at least one effective amount of HGFs; and treating fibrosis disorders comprising administering at least one effective amount of HGFs.
- FIG. 1 is a diagram showing a drug administration schedule in Example 1.
- FIG. 2 is a diagram showing a drug administration schedule in Test A of Example 2.
- FIG. 3 is a diagram showing a drug administration schedule in Test B of Example 2.
- FIG. 4 is a diagram showing the measurement results of GOT, GPT, and ⁇ -GTP in Test A of Example 2.
- FIG. 5 shows the results of the GOT, GPT, hepaplastin test and the measurement of liver Hyp (hydroxyproline) content in Test II of Example 2.
- FIG. 6 is a graph showing the effect of extending the life of HGF on liver fibrosis rats in Test A of Example 3.
- n 5).
- FIG. 7 is a photograph showing the effect of HGF on reducing liver fibrosis in liver fibrosis rats in Test B of Example 3.
- FIG. 8 is a diagram showing the ratio (%) of the fibrous tissue of each individual liver in Example 4.
- HGFs refer to proteins having hepatocyte proliferation activity, and include, for example, HGF (Hepatocyte Growth Factor).
- HGFs used in the present invention those prepared by various methods can be used as long as they are purified to the extent that they can be used as pharmaceuticals.
- HGF HGF-derived neurotrophic factor
- organs such as bone marrow, brain, kidney, placenta
- blood cells such as platelets and leukocytes, plasma, serum, etc. It can be obtained by purification (see FEBS Letters, 224, 312, 1987, Proc. Natl. Acad. Sci. USA, 86, 5844, 1989, etc.).
- HGF can be obtained by culturing primary cultured cells or cell lines that produce HGF and separating and purifying it from cultures (culture supernatants, cultured cells, etc.).
- the recombinant HGF can be obtained from the culture supernatant of this transformant by integrating the vector into an appropriate vector, inserting it into an appropriate host, and transforming (for example, Nature, 342, 440, 1989, Biochem. Biophys. Res. Commun., 163, 967, 1989).
- the host cell is not particularly limited, and various host cells conventionally used in genetic engineering techniques, for example, Escherichia coli, Bacillus subtilis, yeast, filamentous fungi, plant or animal cells, and the like can be used.
- HGF human endothelial growth factor
- carbon tetrachloride is intraperitoneally administered to a rat, and the liver of the rat in a hepatitis state is excised and pulverized.
- the protein can be purified by conventional protein purification methods such as gel column chromatography such as sepharose and heparin sepharose, and HPLC.
- animal cells such as Chinese hamster ovary (CHO) cells and mice, are expressed by an expression vector in which the gene encoding the amino acid sequence of human HGF is inserted into a vector such as sipapilloma virus DNA by genetic recombination.
- C127 cells, monkey COS cells, etc. can be transformed and obtained from the culture supernatant.
- HGFs thus obtained are substantially equivalent to the HGFs
- a portion of the amino acid sequence has been deleted or replaced with another amino acid, and the other amino acid sequence has the same amino acid sequence. It may be partially inserted, one or two or more amino acids may be bound to the N-terminal and / or ⁇ -terminal, or the sugar chain may be similarly deleted or substituted.
- the collagen degradation promoter of the present invention contains the above HGFs as an active ingredient, and the HGFs have an action of promoting collagen degradation (increase in collagenase activity) as shown in the test examples described later. Therefore, it is useful not only for the treatment of the following fibrosis disorders, but also for its prevention, and also for the treatment and prevention of diseases in which collagenase activity is reduced, for example, osteopetrosis.
- the therapeutic agent for fibrosis disorder of the present invention also comprises the above-mentioned HGFs as an active ingredient, and excessive fibroblasts of a connective tissue matrix containing collagen, fibronectin and glycosaminoglycan (GAG).
- HGFs a connective tissue matrix containing collagen, fibronectin and glycosaminoglycan
- GAG glycosaminoglycan
- Atherosclerosis chronic glomerulonephritis, skin keloid formation, progressive systemic sclerosis (PSS), liver fibrosis, pulmonary fibrosis, cystic fibrosis, chronic graft-versus-host disease, scleroderma (local and Whole body), Peyroni's disease, penile fibrosis, urethral stenosis after cystoscopy, internal adhesions after surgery, myelofibrosis, idiopathic retroperitoneal fibrosis
- the agent for promoting collagen degradation and the agent for treating fibrosis disorders of the present invention can be used for promoting collagen degradation and fibrosis in mammals (for example, mice, pigs, sheep, dogs, cats, etc.) in addition to humans. Applied for disability treatment.
- the collagen degradation promoting agent and the therapeutic agent for fibrosis disorders of the present invention can take various preparation forms (for example, liquid preparation, solid preparation, capsule preparation, etc.). Injections, inhalants, suppositories, or oral preparations together with conventional carriers.
- the injection can be prepared by a conventional method. For example, after dissolving HGFs in an appropriate solvent (eg, sterilized water, buffer, physiological saline, etc.), sterilize by filtering through a filter or the like. Then, it can be prepared by filling in a sterile container.
- the HGF content in the injection is usually adjusted to about 0.0002 to 0.2 (W / V%), preferably about 0.001 to UW / V%.
- Oral drugs include, for example, tablets, granules, fine granules, powders, soft or hard capsules, solutions, emulsions, suspensions, syrups, etc. It can be prepared according to a conventional method of formulation. Suppositories can also be prepared by a conventional method using a conventional base (for example, cabbage fat, lauric fat, glycerinated gelatin, macrogol, witepsol, etc.). Also, inhalants can be prepared according to conventional methods for preparation.
- the content of HGFs in the preparation can be appropriately adjusted depending on the dosage form, applicable disease and the like.
- a stabilizer is preferably added.
- the stabilizer include albumin, globulin, gelatin, glycine, mannitol, glucose, dextran, sorbitol, ethylene glycol and the like.
- the preparation of the present invention may contain additives necessary for preparation, for example, excipients, solubilizers, antioxidants, soothing agents, isotonic agents and the like.
- a liquid preparation it is desirable to store it after freezing or freezing it to remove water.
- the lyophilized preparation is reconstituted with distilled water for injection and used before use.
- the agent for promoting collagen degradation and the agent for treating fibrosis disorders of the present invention can be administered by an appropriate administration route depending on the form of the preparation.
- injection form It can be administered to veins, arteries, subcutaneous, intramuscular, etc.
- the dose is adjusted appropriately depending on the patient's condition, age, weight, etc., but is usually 0.05 mg to 500 ing, preferably 1 mg to 100 mg as HGF, and is divided into once or several times a day. Is appropriate.
- the HGFs which are the active ingredients of the present invention, promote the degradation of collagen (increase in collagenase activity), and thus can effectively treat fibrosis disorders. Therefore, according to the present invention, prevention of diseases in which collagenase activity is reduced (for example, osteopetrosis) and the above-mentioned fibrotic disorders characterized by excessive fibroblast production of connective tissue matrix. ⁇ Can be treated.
- the above substance was dissolved in 0.01 M PBS having a pH of 7.0, the total amount was adjusted to 20 ml, and after sterilization, 2 ml each was dispensed into a vial and sealed by freeze-drying.
- Example 1 HGF suppresses fibrosis and improves symptom on dimethylnitrosamine liver fibrosis rat
- Dimethylnitrosamine (DMN) was administered intraperitoneally every week on Tuesday, Wednesday and Thursday at a dose of 10 ⁇ g for 4 weeks.
- HGF was intravenously administered at 500 cg / kg twice a day (1,000 g / kg / day) for 28 days from the first DMN administration.
- the dosing schedule is shown in FIG. On day 29, the test rat was subjected to the following measurement.
- Rats were dissected and liver weights were determined.
- the content of hydroxylamine in liver tissue (Hyp; an indicator of fibrosis) and the activity of collagenase (collagenase) were determined by the method of Kivirikko et al. (Anal. Biochem, 19, 249, 1967) and Murawaki et al. (J. Biochem, 108, 241, 1990).
- the DNA and protein content in the liver tissue were measured by the modified method of Burton (Biochem, J, 62, 315, 1956) and the protein assay kit (manufactured by Biorat), respectively. The results are shown in Table 1.
- blood was collected from the posterior vena cava and the collected serum was analyzed for clinical biochemistry by a Hitachi 7150 automatic analyzer.
- the blood test was performed using a multi-item automatic blood cell counter (E-400, Sysmex) to measure the platelet count, white blood cell count, red blood cell count, hematocrit value, and hemoglobin concentration using EDT A-added blood collected from the posterior vena cava. ).
- Plasma mixed with a 3.8% aqueous solution of sodium citrate and blood collected from the posterior vena cava at a ratio of 1: 9 was used for plasma coagulation (prothrombin time, fibrinogen content, hepaplasmin test and The coagulation time according to the thrombotest was measured using an automatic coagulation ability measuring device (KC-40). The results are shown in Table 2.
- Table 1 Plasma mixed with a 3.8% aqueous solution of sodium citrate and blood collected from the posterior vena cava at a ratio of 1: 9 was used for plasma coagulation (prothrombin time, fibrinogen content, hepaplasmin test and The coagulation time according to the thrombotest was measured using an automatic coagulation ability measuring device (KC-40). The results are shown in Table 2. Table 1
- a male liver rat (6 weeks old) was orally administered with carbon tetrachloride every month and Thursday at a dose of 0.7 m 1 / kg for 12 weeks to prepare a liver fibrosis model.
- This carbon tetrachloride liver fibrosis rat was subjected to the following two tests.
- HGF was added to the above carbon tetrachloride hepatic fibrosis rats (13-14 animals per group) twice daily at 50 and 500 ⁇ gZkg (100 and 1 OOO ⁇ g / kg / day). It was administered intravenously for 7 days.
- the dosing schedule is shown in FIG. Changes in serum GOT, GPT, and ⁇ -GTP levels on days 3, 5, and 7 from the start of HGF administration were compared with those of the vehicle-administered group (control).
- Fig. 4 shows the results.
- HGF hepatic fibrosis rats of 12 to 13 animals per group
- HGF was continuously instilled at a rate of 100 and 1000 Atg / kg / day from a catheter placed in the jugular vein. Dissection was performed 72 hours after the start of HGF administration.
- the dosing schedule is shown in FIG. GOT, GPT, serum total protein and albumin in serum were mixed with a 3.8% aqueous solution of sodium citrate and blood collected from the posterior vena cava at a ratio of 1: 9 using a Hitachi 71500 automatic analyzer.
- the coagulation time of the hepaplastin test was measured by an automatic coagulation ability measuring apparatus (KC-140).
- the hydroxyproline content (Hyp) in liver tissue as an indicator of fibrosis was measured by the method of Kivirikko et al. The results are shown in Table 3 and Figure 5.
- HGF showed a dose-dependent improvement in liver function test values, recovery of hypoproteinemia, and improvement of fibrosis after 100 ⁇ g / kg g day or more. A decrease in the medium hydroxyproline content was observed.
- the survival rate of the HGF-administered group and the non-administered group on liver fibrosis rats induced by DMN was examined.
- the administration schedule of the drug is shown in the upper part of FIG. DMN dissolved in physiological saline at a concentration of 1% was combined with DMN that weighed 1 kg SD male rat. Then, intraperitoneal administration was performed at a rate of 11 times three times a week for 6 weeks on the day indicated by the arrow. Human HGF or physiological saline was intravenously administered daily from the 21st day after the start of DMN administration for the period indicated by the hatched band, and the survival rate (%) of the test rats was examined daily. Figure 6 shows the results. In FIG.
- the rat was killed on day 42 and the liver was collected for the detection of fibrotic substrate.
- the liver was quickly frozen in an OTC compound, and the prepared sections were anti-rat collagen type I antibody derived from Egret (LSL) and anti-Egret Ig from fluorescently labeled goats. After reacting with the G antibody, the specimen was photographed.
- Figure 7 shows the results.
- Prothrombin time PT
- albumin A lb
- plasma glutamate oxalate acetate Serum
- DMN was intraperitoneally administered to a 5-week-old male SD rat at a dose of g three times a week (month, fire, water) for 4 weeks to prepare a liver / fibrotic rat.
- One mg / kg of HGF or 1 ml / kg of a solvent (phosphate buffered saline containing HSA 2.5 nigZm1, 800.01% Tween) was added to this rat for 5 weeks.
- Time (Mon, Tue, Wed, Thu, Fri) Administered from the start of DMN administration until 4th day of 4th week.
- the rat was sacrificed, and the liver was collected and fixed in neutral formalin.
- the tissue was stained with Matsuson trichrome to stain fibrous tissues.
- the liver of a healthy rat was similarly stained.
- an image analyzer T. Watanabe et al. Analytical Cellular Pathology 4 (3), 248, 1992
- the area of fibrotic tissue in the total area of the tissue section was determined for the liver tissue specimen of each stained individual.
- the degree of fibrillation was calculated and compared.
- the number of individuals used in the analysis was 8 in healthy rats, 8 in DMN + solvent-administered group (DMN), and 8 in DMN + HGF-administered group (HGF + DMN). There were 6 cases excluding the affected individuals.
- DMN increased the percentage of fibrous tissue in liver tissue to 7.3% compared to an average of 1.3% when compared to healthy rats.
- DMN + HGF decreased to 2.8%, indicating that administration of HGF reduced liver fibrosis by DMN.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/732,332 US5840311A (en) | 1994-04-28 | 1995-04-25 | Agent accelerating collagen decomposition |
DE69535593T DE69535593T2 (de) | 1994-04-28 | 1995-04-25 | Verwendung von hgf zur herstellung eines arzneimittels zur behandlung von lungenfibrose |
EP95917466A EP0784980B1 (en) | 1994-04-28 | 1995-04-25 | Use of hgf for the manufacture of a medicament for the treatment of pulmonary fibrosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11437294A JP3818322B2 (ja) | 1994-04-28 | 1994-04-28 | コラーゲン分解促進剤 |
JP6/114372 | 1994-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995029694A1 true WO1995029694A1 (fr) | 1995-11-09 |
Family
ID=14636057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000822 WO1995029694A1 (fr) | 1994-04-28 | 1995-04-25 | Accelerateur d'hydrolyse du collegene |
Country Status (7)
Country | Link |
---|---|
US (2) | US5840311A (ja) |
EP (3) | EP2163254A1 (ja) |
JP (1) | JP3818322B2 (ja) |
AT (1) | ATE372781T1 (ja) |
DE (1) | DE69535593T2 (ja) |
ES (1) | ES2289742T3 (ja) |
WO (1) | WO1995029694A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997009997A1 (en) * | 1995-09-12 | 1997-03-20 | Genentech, Inc. | Cystic fibrosis therapy |
JP4531990B2 (ja) * | 1999-03-25 | 2010-08-25 | 田辺三菱製薬株式会社 | 間質性肺炎・肺線維症の予防・治療薬 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3818322B2 (ja) * | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
JP3927248B2 (ja) * | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Hgf凍結乾燥製剤 |
ID29293A (id) | 1997-07-22 | 1999-01-28 | Shionogi & Co | KOMPOSISI UNTUK MENGOBATI ATAU MENCEGAH GLOMERULOPATI (Pecahan dari No. W20000054) |
US6887477B1 (en) | 1998-08-05 | 2005-05-03 | Tomokazu Nagano | Method of treating ischemic disease by intramuscular administration of Hepatocyte growth factor |
DE69934336T2 (de) * | 1999-09-09 | 2007-07-05 | Hadasit Medical Research Services & Development Co. Ltd. | Verwendung von halofuginone zur behandlung von urethralstriktur |
US7601365B2 (en) * | 2000-08-28 | 2009-10-13 | Damavand Wound, AB | Synergetic effects of HGF and antibacterial treatment |
DE602004025748D1 (de) | 2003-11-20 | 2010-04-08 | Shinshu Tlo Co Ltd | Hydrocephalus-behandlung |
PT1734970E (pt) | 2004-03-12 | 2015-03-11 | Intercept Pharmaceuticals Inc | Tratamento de fibrose utilizando ligandos de rfx |
CN101102788A (zh) | 2005-01-24 | 2008-01-09 | 克霖固鲁制药股份有限公司 | 移植器官纤维化抑制剂 |
US20110230407A1 (en) * | 2005-03-14 | 2011-09-22 | Alexander Yuzhakov | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
ES2262444B1 (es) * | 2006-03-01 | 2007-12-16 | Universidad De Leon | Uso de plasma rico en plaquetas para la preparacion de un medicamento para combatir la fribrosis. |
JP5051725B2 (ja) * | 2006-04-20 | 2012-10-17 | 国立大学法人大阪大学 | ポリグルタミン病の治療剤又は発病抑制剤 |
US8772326B2 (en) | 2008-07-10 | 2014-07-08 | Anigion Biomedica Corp. | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
ES2763556T3 (es) | 2013-02-07 | 2020-05-29 | Scifluor Life Sciences Inc | Antagonistas fluorados de integrina |
EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
JP2018514568A (ja) | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
WO2017189828A1 (en) | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
KR101780597B1 (ko) * | 2016-07-25 | 2017-09-20 | 서울대학교병원 | TIF1γ의 발현 또는 활성 증강제를 유효성분으로 포함하는 간 섬유화 또는 간경화 예방 또는 치료용 조성물 |
WO2018145147A1 (en) * | 2017-02-07 | 2018-08-16 | David Chin | A method of treating a fibrotic condition associated with excessive collagen formation using activators of the collagenase production pathway. |
BR112021020367A2 (pt) | 2019-04-11 | 2021-12-07 | Angion Biomedica Corp | Formas sólidas de (e)-3-[2-(2-tienil)vinil] -1h-pirazol |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0492614A2 (en) * | 1990-12-28 | 1992-07-01 | NAKAMURA, Toshikazu | Epitheliocyte growth accelerator |
JPH05213733A (ja) * | 1992-02-05 | 1993-08-24 | Sansho Seiyaku Co Ltd | 皮膚化粧料 |
JPH06172207A (ja) * | 1992-10-08 | 1994-06-21 | Toshiichi Nakamura | 肺傷害治療剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2564486B2 (ja) * | 1986-07-14 | 1996-12-18 | 修治 橋本 | 肝細胞増殖因子 |
JP2784455B2 (ja) * | 1990-05-09 | 1998-08-06 | 敏一 中村 | 肝硬変治療剤 |
JP2750372B2 (ja) * | 1990-06-19 | 1998-05-13 | 敏一 中村 | 賢疾患治療剤 |
JP3818322B2 (ja) * | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
-
1994
- 1994-04-28 JP JP11437294A patent/JP3818322B2/ja not_active Expired - Fee Related
-
1995
- 1995-04-25 ES ES95917466T patent/ES2289742T3/es not_active Expired - Lifetime
- 1995-04-25 DE DE69535593T patent/DE69535593T2/de not_active Expired - Lifetime
- 1995-04-25 EP EP09011635A patent/EP2163254A1/en not_active Withdrawn
- 1995-04-25 US US08/732,332 patent/US5840311A/en not_active Expired - Lifetime
- 1995-04-25 EP EP07002486A patent/EP1776959A3/en not_active Withdrawn
- 1995-04-25 WO PCT/JP1995/000822 patent/WO1995029694A1/ja active IP Right Grant
- 1995-04-25 AT AT95917466T patent/ATE372781T1/de not_active IP Right Cessation
- 1995-04-25 EP EP95917466A patent/EP0784980B1/en not_active Expired - Lifetime
-
1998
- 1998-05-06 US US09/072,742 patent/US6303126B1/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0492614A2 (en) * | 1990-12-28 | 1992-07-01 | NAKAMURA, Toshikazu | Epitheliocyte growth accelerator |
JPH05213733A (ja) * | 1992-02-05 | 1993-08-24 | Sansho Seiyaku Co Ltd | 皮膚化粧料 |
JPH06172207A (ja) * | 1992-10-08 | 1994-06-21 | Toshiichi Nakamura | 肺傷害治療剤 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997009997A1 (en) * | 1995-09-12 | 1997-03-20 | Genentech, Inc. | Cystic fibrosis therapy |
US5855918A (en) * | 1995-09-12 | 1999-01-05 | Genentech, Inc. | Cystic fibrosis therapy |
US6033688A (en) * | 1995-09-12 | 2000-03-07 | Genentech, Inc. | Cystic fibrosis therapy |
JP4531990B2 (ja) * | 1999-03-25 | 2010-08-25 | 田辺三菱製薬株式会社 | 間質性肺炎・肺線維症の予防・治療薬 |
Also Published As
Publication number | Publication date |
---|---|
EP1776959A2 (en) | 2007-04-25 |
ES2289742T3 (es) | 2008-02-01 |
JPH07300426A (ja) | 1995-11-14 |
JP3818322B2 (ja) | 2006-09-06 |
EP0784980B1 (en) | 2007-09-12 |
ATE372781T1 (de) | 2007-09-15 |
US6303126B1 (en) | 2001-10-16 |
US5840311A (en) | 1998-11-24 |
DE69535593D1 (de) | 2007-10-25 |
EP0784980A1 (en) | 1997-07-23 |
EP2163254A1 (en) | 2010-03-17 |
DE69535593T2 (de) | 2008-06-12 |
EP0784980A4 (en) | 2000-01-26 |
EP1776959A3 (en) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995029694A1 (fr) | Accelerateur d'hydrolyse du collegene | |
AU623181B2 (en) | Use of gamma-interferon for the treatment of vascular stenosis | |
JP2010100664A (ja) | 急性腎不全治療用hgf | |
JPH0925241A (ja) | Hgf凍結乾燥製剤 | |
JP2002371006A (ja) | 肺線維症予防および/または進行防止剤 | |
WO1998024467A1 (fr) | Medicaments contre l'hepatite fulminante | |
EP0914829B1 (en) | Preventives and/or remedies for multiple organ failure | |
JP3977452B2 (ja) | 動脈疾患治療剤 | |
JPH08268906A (ja) | 肺線維症予防剤 | |
JP3904268B2 (ja) | Hgf医薬製剤 | |
JP3619526B2 (ja) | Tcf−iiを有効成分とする肝臓疾患治療剤 | |
JP3245202B2 (ja) | 新規骨形成誘導蛋白質及びそれを有効成分とする骨形成誘導剤 | |
WO2019087184A1 (en) | Methods and compositions for reducing lung injury associated with lung transplantation | |
CN110898080B (zh) | 鲎血浆在促生长发育中的应用 | |
JPH10194986A (ja) | 移植肝機能改善・再生促進剤 | |
WO1999027951A1 (fr) | Preparation pour l'admission intraveineuse continue | |
JPH05301824A (ja) | 肝実質細胞増殖剤 | |
JPH1129493A (ja) | 放射線障害予防及び/又は治療剤 | |
JPH0827026A (ja) | 肝疾患の予防・治療薬 | |
JPH11199508A (ja) | 臓器不全治療剤 | |
JP2000344681A (ja) | Hgf含有医薬 | |
JPH0987199A (ja) | 腎糸球体疾患治療剤 | |
JP2007277268A (ja) | 劇症肝炎疾患治療剤 | |
JPH07316071A (ja) | 筋ジストロフィー治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995917466 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08732332 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995917466 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995917466 Country of ref document: EP |